Immunovant, Inc. — Director's Dealing 2023

Oct 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2023-10-05

Reporting Person: Butchko Julia G. (Chief Development Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-05	Common Stock	S	296	$35.54	Disposed	415964	Direct
2023-10-05	Common Stock	S	1439	$36.39	Disposed	414525	Direct

Footnotes

F1: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,406 of these RSUs vested on October 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F2: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.90 - $35.89 per share, inclusive. The Reporting Person undertakes to provide to
the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the
range set forth in this footnote to this Form 4.

F3: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.92 - $36.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4